GLA
LGND icon

Great Lakes Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Great Lakes Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-14,358
Closed -$691K – 545
2015
Q1 		$691K Buy
+14,358
New +$550K 0.02% 392

Other funds holding LGND

William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Lakes Advisors's LGND Position: Q2 2015 in Review

Great Lakes Advisors sold out of Ligand Pharmaceuticals (LGND) in Q2 2015, closing a stake of 14,358 shares — an estimated $691K sold.

Great Lakes Advisors first reported a position in LGND in Q1 2015 and held it in 1 quarter. The position peaked at $691K in Q1 2015. 215 funds tracked by Wall St. Rank hold LGND as of Q2 2015.

  • Great Lakes Advisors reported no remaining Ligand Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Great Lakes Advisors sold 14,358 Ligand Pharmaceuticals shares in Q2 2015, an estimated $691K.
  • Great Lakes Advisors first reported a position in Ligand Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Great Lakes Advisors's Ligand Pharmaceuticals position peaked at $691K in Q1 2015.
  • 215 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2015.

Based on Great Lakes Advisors's 13F filing for Q2 2015, filed 12 Aug 2015.